PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Magic pills: new oral drugs to treat chronic lymphocytic leukemia.

Abstract A deeper understanding of chronic lymphocytic leukemia (CLL) biology has led to the identification of new promising therapeutic targets. Different classes of molecules are currently under investigation and novel oral drugs have recently been approved or are in a late stage of clinical development. Areas covered: We present biological data illustrating the heterogeneous mechanisms of action of new oral drugs in CLL. Moreover, we provide clinical data from phase I to III studies, and discuss efficacy and side effects profile of these new therapies. Data are derived from peer-reviewed articles indexed in PubMed and from abstracts presented at major international meetings. Expert opinion: Novel oral drugs represent a valuable alternative to chemo-immunotherapy for patients with CLL, especially when high-risk disease features are present and when age or comorbidities preclude the use of standard treatments. Based on data from ongoing clinical trials, the indications of already approved agents will most likely be expanded and new options will soon be available. Moreover, treatment combinations will broaden the therapeutic armamentarium of physicians treating CLL. The availability of multiple choices is of benefit for patients with CLL, but also represents a challenge for the need of choosing the right drug for each patient.
PMID
Related Publications

The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.

Management of elderly and unfit patients with chronic lymphocytic leukemia.

Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.

Current Treatment of Chronic Lymphocytic Leukemia.

Chronic lymphocytic leukemia therapy: new targeted therapies on the way.

Authors

Mayor MeshTerms
Keywords

Chronic lymphocytic leukemia

ibrutinib

idelalisib

new drugs

target therapy

venetoclax

Journal Title expert opinion on pharmacotherapy
Publication Year Start




PMID- 28234562
OWN - NLM
STAT- In-Process
DA  - 20170224
LR  - 20170224
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 18
IP  - 4
DP  - 2017 Mar
TI  - Magic pills: new oral drugs to treat chronic lymphocytic leukemia.
PG  - 411-425
LID - 10.1080/14656566.2017.1293655 [doi]
AB  - INTRODUCTION: A deeper understanding of chronic lymphocytic leukemia (CLL)
      biology has led to the identification of new promising therapeutic targets.
      Different classes of molecules are currently under investigation and novel oral
      drugs have recently been approved or are in a late stage of clinical development.
      Areas covered: We present biological data illustrating the heterogeneous
      mechanisms of action of new oral drugs in CLL. Moreover, we provide clinical data
      from phase I to III studies, and discuss efficacy and side effects profile of
      these new therapies. Data are derived from peer-reviewed articles indexed in
      PubMed and from abstracts presented at major international meetings. Expert
      opinion: Novel oral drugs represent a valuable alternative to chemo-immunotherapy
      for patients with CLL, especially when high-risk disease features are present and
      when age or comorbidities preclude the use of standard treatments. Based on data 
      from ongoing clinical trials, the indications of already approved agents will
      most likely be expanded and new options will soon be available. Moreover,
      treatment combinations will broaden the therapeutic armamentarium of physicians
      treating CLL. The availability of multiple choices is of benefit for patients
      with CLL, but also represents a challenge for the need of choosing the right drug
      for each patient.
FAU - Vitale, Candida
AU  - Vitale C
AD  - a Division of Hematology , University of Torino, AOU Citta della Salute e della
      Scienza di Torino , Torino , Italy.
AD  - b Department of Molecular Biotechnology and Health Sciences , University of
      Torino , Torino , Italy.
FAU - Griggio, Valentina
AU  - Griggio V
AD  - a Division of Hematology , University of Torino, AOU Citta della Salute e della
      Scienza di Torino , Torino , Italy.
AD  - b Department of Molecular Biotechnology and Health Sciences , University of
      Torino , Torino , Italy.
FAU - Todaro, Maria
AU  - Todaro M
AD  - a Division of Hematology , University of Torino, AOU Citta della Salute e della
      Scienza di Torino , Torino , Italy.
AD  - b Department of Molecular Biotechnology and Health Sciences , University of
      Torino , Torino , Italy.
FAU - Salvetti, Chiara
AU  - Salvetti C
AD  - a Division of Hematology , University of Torino, AOU Citta della Salute e della
      Scienza di Torino , Torino , Italy.
AD  - b Department of Molecular Biotechnology and Health Sciences , University of
      Torino , Torino , Italy.
FAU - Boccadoro, Mario
AU  - Boccadoro M
AD  - a Division of Hematology , University of Torino, AOU Citta della Salute e della
      Scienza di Torino , Torino , Italy.
AD  - b Department of Molecular Biotechnology and Health Sciences , University of
      Torino , Torino , Italy.
FAU - Coscia, Marta
AU  - Coscia M
AD  - a Division of Hematology , University of Torino, AOU Citta della Salute e della
      Scienza di Torino , Torino , Italy.
AD  - b Department of Molecular Biotechnology and Health Sciences , University of
      Torino , Torino , Italy.
LA  - eng
PT  - Journal Article
DEP - 20170222
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
OTO - NOTNLM
OT  - Chronic lymphocytic leukemia
OT  - ibrutinib
OT  - idelalisib
OT  - new drugs
OT  - target therapy
OT  - venetoclax
EDAT- 2017/02/25 06:00
MHDA- 2017/02/25 06:00
CRDT- 2017/02/25 06:00
AID - 10.1080/14656566.2017.1293655 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2017 Mar;18(4):411-425. doi:
      10.1080/14656566.2017.1293655. Epub 2017 Feb 22.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>